查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012800

適體市場：按類型、技術、應用和最終用戶分類－2026-2030年全球市場預測

Aptamers Market by Type, Technology, Application, End-User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年適體市值為 2.5435 億美元，預計到 2025 年將成長至 2.8551 億美元，複合年成長率為 12.43%，到 2030 年將達到 5.1377 億美元。

主要市場統計數據
基準年 2024 2.5435億美元
預計年份：2025年 2.8551億美元
預測年份 2030 5.1377億美元
複合年成長率 (%) 12.43%

利用高精度粘合劑在生命科學領域掀起適體革命：推動下一代診斷、治療和安全解決方案的發展。

適體的出現開啟了生命科學領域中分子辨識的革命性時代。與傳統抗體不同，適體利用合成的核酸或胜肽結構，對多種標靶實現卓越的特異性和親和性。這種精準的結合能力實現了前所未有的高度客製化，為診斷、治療和環境監測等領域開闢了新的可能性。隨著研究的活性化，適體的模組化特性使得結合基序的快速迭代和最佳化成為可能，從而能夠適應新的生物標記和不斷變化的疾病情況。

追蹤適體開發領域的模式轉移：重點介紹從傳統篩選方法到高速、高通量分子辨識平台的進展

隨著篩選調查方法和技術平台的演進，適體領域發生了翻天覆地的變化。傳統的體外篩選過程正逐漸被更精細的方法所取代，這些方法能夠縮短發現時間並提高結合特異性。微流體控系統的突破性進展使得連續流動篩選成為可能，且試劑消耗量極低；而高通量定序的整合則顯著提高了候選適體庫篩選的準確性。

檢驗2025 年美國提高關稅對全球適體供應鏈、研究合作與市場動態的連鎖反應。

2025年，美國對關鍵原料和設備加徵關稅，對全球適體生態系統產生了深遠影響。修飾核苷酸和專用層析管柱等關鍵試劑面臨成本上升的壓力，迫使各機構重新評估其籌資策略和庫存管理。新關稅也影響了電泳系統和微流體裝置等高精度設備的進口，而這些設備正是適體分選工作流程的基礎。

根據類型、技術、應用和最終用戶確定關鍵市場細分趨勢，突顯目標機會。

依類型進行市場細分可以明顯看出核酸適體和胜肽適體之間的區別，二者各有其獨特的優勢。在核酸適體中，DNA適體具有優異的熱穩定性和易於合成的特點，而RNA適體則展現出動態的二級結構，適用於辨識複雜的標靶。肽適體由短的胺基酸序列組成，具有更強的抗蛋白酶能力，並且能夠識別核酸適體無法觸及的獨特抗原表位。

了解對美洲、歐洲、中東和非洲以及亞太地區適體市場的影響，並推動策略擴張重點。

憑藉著雄厚的研發資金、強大的生物技術基礎和寬鬆的法規環境，美洲在適體創新領域持續保持主導地位。北美各地的關鍵中心促進了學術研究機構和商業開發人員之間的緊密合作，加速了基於適體的診斷和治療方法向臨床試驗的轉化。此外，各機構也建立了策略採購夥伴關係，確保能夠在國內獲得必要的試劑和設備。

介紹領先的適體創新者和策略參與者，他們透過專業平台、合作夥伴關係和技術投資來推動競爭差異化。

適體領域的領先創新者正透過專有技術和策略合作的協同效應來脫穎而出。一些專業供應商已建構了以高通量分選平台和化學修飾技術為核心的龐大智慧財產權組合，使其能夠為複雜靶點提供客製化的結合解決方案。與製藥公司的夥伴關係模式正在加速適體-藥物偶聯物和診斷檢測方法的共同開發，從而縮短產品上市時間。

為產業領導者提供策略建議，以利用適體市場的演變：增強競爭力並建立協作生態系統

產業領導者應優先考慮建立多樣化的適體篩選平台，以降低依賴單一技術所帶來的風險。透過整合互補的調查方法，企業可以建構出針對不同標靶類別的藥物發現工作流程，並加速候選化合物的篩選。同時，與多家區域供應商建立穩固的供應鏈合作關係，能夠增強企業應對關稅波動和物流中斷的能力。

分析適體市場趨勢所採用的嚴格調查方法詳情：檢驗資料來源，確保分析的透明度和可靠性。

本分析的調查方法嚴謹地結合了第一手資料和第二手資料，以確保全面性和一致性。最初的第二手資料研究包括對科學文獻、專利資料庫、監管指南和白皮書的廣泛查閱，以了解適體領域的歷史趨勢和新興技術。此外，也利用專有資料庫收集了關於篩選平台、修飾化學和應用開發的檢驗資訊。

本報告總結了對適體技術未來前景的策略見解，並強調了精準醫療和安全解決方案的必要性。

適體技術的演進正在革新分子識別領域，這些用途廣泛的試劑被視為下一代診斷、治療和安全解決方案的基礎。調查方法和化學修飾方面的技術創新正在推動性能提升，而適應性供應鏈策略則有助於緩解關稅波動等外部壓力。市場區隔洞察凸顯了在類型、技術和應用等維度上採取針對性策略的重要性，而區域分析則揭示了美洲、歐洲、中東和非洲以及亞太地區不同的成長軌跡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：適體市場：依類型分類

  • 核酸適體
    • DNA適體
    • RNA適體
  • 胜肽適體

第9章 適體市場：依技術分類

  • SELEX 以外的技術
  • SELEX技術
    • 毛細管電泳 (CE) - SELEX
    • 捕獲 SELEX
    • 塞勒克斯
    • 氧化石墨烯（GO）-SELEX
    • 微流體SELEX
    • 標準 SELEX

第10章 適體市場：依應用領域分類

  • 臨床診斷
    • 心血管和代謝疾病的診斷
    • 遺傳性和罕見疾病篩檢
    • 感染疾病診斷
    • 神經系統疾病的診斷
    • 腫瘤診斷
  • 食品和環境安全
    • 農業檢驗
    • 環境監測
    • 食品安全檢查
  • 治療和藥物開發
    • 心血管疾病
    • 感染疾病
    • 神經系統疾病
    • 腫瘤學
    • 罕見疾病和遺傳疾病

第11章 適體市場：依最終用戶分類

  • 學術和研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第12章 適體市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 適體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 適體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國適體市場

第16章：中國適體市場

第17章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • 2bind GmbH
  • Agilent Technologies, Inc.
  • Aptadel Therapeutics SL
  • Aptagen, LLC
  • AptaMatrix, Inc.
  • Aptamer Group PLC
  • AptaTargets SL
  • AptusBiotech
  • Astellas Pharma Inc.
  • Base Pair Biotechnologies, Inc.
  • Basking Biosciences
  • Bio-Techne Corporation
  • Biogenes Technologies Sdn. Bhd.
  • Biotage
  • Cage Bio, Inc.
  • Creative Biogene
  • Creative Biolabs
  • Drive Therapeutics, LLC
  • F. Hoffmann-La Roche AG
  • Kaneka Eurogentec SA
  • NEC Corporation
  • NeoVentures Biotechnology Inc.
  • NOVAPTECH, SAS
  • Profacgen
  • SomaLogic, Inc.
  • TAGCyx Biotechnologies, Inc.
  • Veraptus
  • Vivonics Inc.
  • Zentek Ltd.
Product Code: MRR-4358BACA838E

The Aptamers Market was valued at USD 254.35 million in 2024 and is projected to grow to USD 285.51 million in 2025, with a CAGR of 12.43%, reaching USD 513.77 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 254.35 million
Estimated Year [2025] USD 285.51 million
Forecast Year [2030] USD 513.77 million
CAGR (%) 12.43%

Establishing the Aptamer Revolution in Life Sciences with Precision Binding Agents Fueling Next Generation Diagnostics Therapeutics and Safety Solutions

The advent of aptamers has ushered in a transformative era for molecular recognition in life sciences. Unlike traditional antibodies, aptamers leverage their synthetic nucleic acid or peptide structures to achieve exceptional specificity and affinity for a diverse array of targets. This precision binding capability has opened new doors for diagnostics, therapeutics, and environmental monitoring by offering a level of customization previously unattainable. As research intensifies, the modularity of aptamers enables rapid iteration of binding motifs to adapt to emerging biomarkers and evolving disease landscapes.

Moreover, the scalability of aptamer synthesis presents distinct advantages in manufacturing and cost management. The solid-phase synthesis of nucleic acid aptamers circumvents many constraints associated with biological production systems, streamlining quality control and reducing batch variability. Consequently, organizations are increasingly able to deploy aptamers in high-throughput screening contexts, facilitating accelerated discovery cycles.

The convergence of enhanced selection technologies with advanced chemical modification strategies further reinforces the role of aptamers as next-generation molecular tools. By integrating stability enhancements and functional conjugations, these molecules are primed to penetrate new application domains, setting the stage for unprecedented advancements in precision diagnostics and targeted therapies.

Tracking Paradigm Shifts in Aptamer Development Highlighting Advances from Traditional Selection Methods to Rapid High Throughput Molecular Recognition Platforms

The aptamer field has experienced seismic shifts as selection methodologies and technological platforms evolve. Traditional in vitro evolution processes have given way to refined approaches that accelerate discovery timelines and enhance binding specificity. Breakthroughs in microfluidic-based systems have minimized reagent consumption while enabling continuous flow selection, and the integration of high-throughput sequencing has drastically improved the resolution of candidate pools.

Concurrently, novel non-SELEX-based modalities have emerged to complement established procedures, offering alternative pathways for aptamer generation without the iterative cycles inherent to classical techniques. These complementary methods are fostering multidisciplinary collaborations, marrying principles of nanomaterials science, bioinformatics, and synthetic chemistry to refine aptamer performance.

Examining the Ripple Effects of Enhanced United States Tariffs in 2025 on Global Aptamer Supply Chains Research Collaborations and Market Dynamics

In 2025, the imposition of elevated tariffs by the United States on key raw materials and equipment has reverberated across the global aptamer ecosystem. Critical reagents such as modified nucleotides and specialized chromatography columns now face increased cost pressures, prompting organizations to reassess sourcing strategies and inventory management. The new tariffs have also affected the import of high-precision instrumentation, including electrophoresis units and microfluidic devices, which are foundational to aptamer selection workflows.

As a result, research institutions and commercial developers are exploring alternative supply channels and regional manufacturing partnerships to mitigate tariff-induced constraints. Some companies have begun forging agreements with domestic suppliers or diversifying vendor portfolios to maintain continuity of critical experiments. Furthermore, collaborative consortia are emerging to pool procurement power, sharing infrastructure and resources to offset elevated operational expenses.

These adaptive strategies underscore the importance of proactive trade and procurement planning. By carefully aligning supply chain configurations with regulatory landscapes, organizations can sustain research momentum and safeguard investment in long-term R&D initiatives despite fluctuating trade policies.

Unveiling Critical Market Segmentation Dynamics Based on Type Technology Application and End User to Illuminate Targeted Opportunities

Market segmentation by type reveals a clear bifurcation between nucleic acid aptamers and peptide aptamers, each offering distinct advantages. Within the nucleic acid category, DNA aptamers provide robust thermal stability and ease of synthesis, while RNA aptamers exhibit dynamic secondary structures well-suited for intricate target recognition. Peptide aptamers, constructed from short amino acid sequences, deliver enhanced protease resistance and can access unique epitopes inaccessible to nucleic acids.

From a technological perspective, the landscape divides into non-SELEX-based methodologies and SELEX technology. SELEX remains the cornerstone of aptamer discovery, with sophisticated variants including capillary electrophoresis-SELEX, which enables rapid separation of bound from unbound species, and capture-SELEX, where target immobilization streamlines selection. Cell-SELEX leverages live-cell environments to identify functionally relevant ligands, while graphene oxide-SELEX exploits π-π interactions to enrich high-affinity sequences. Microfluidic SELEX platforms integrate selection and amplification within nanoscale channels, and standard SELEX continues to serve as a reliable baseline methodology.

Applications span clinical diagnostics, food and environmental safety, and therapeutics and drug development. In clinical diagnostics, advancements in cardiovascular and metabolic disease screening, genetic and rare disease detection, infectious pathogen identification, neurological disorder analysis, and oncology biomarker assays are driving diagnostic innovation. Environmental and food safety applications encompass agricultural contaminant testing, ecosystem monitoring, and foodborne pathogen surveillance. Therapeutic pursuits target cardiovascular diseases, infectious agents, neurodegenerative disorders, cancer, and rare genetic conditions, highlighting aptamers' versatility.

End users range from academic and research institutions pioneering fundamental discoveries to hospital and clinical settings implementing diagnostic assays, as well as pharmaceutical and biotechnology companies integrating aptamer platforms into drug discovery and development pipelines.

Deciphering Regional Aptamer Market Influences across Americas Europe Middle East Africa and Asia Pacific Driving Strategic Expansion Priorities

The Americas continue to lead in aptamer innovation, underpinned by substantial R&D funding, robust biotechnology infrastructure, and a receptive regulatory environment. Key hubs across North America facilitate close collaboration between academic laboratories and commercial developers, driving rapid translation of aptamer-based diagnostics and therapeutics into clinical trials. Additionally, strategic procurement partnerships have emerged, enabling organizations to secure essential reagents and instrumentation domestically.

Europe Middle East and Africa exhibit a diverse landscape with harmonized regulatory frameworks supporting multi-country clinical studies. Significant investment in personalized medicine initiatives has accelerated diagnostic adoption, particularly within oncology and rare disease screening programs. Meanwhile, environmental monitoring directives across the European Union and adjacent regions are propelling the integration of aptamer-based sensors for pollutant and pathogen detection.

Asia-Pacific presents a fast-expanding market characterized by government-led innovation strategies, cost-effective manufacturing capabilities, and increasing local expertise in nucleic acid chemistry. Rapid urbanization and rising healthcare expenditures are driving demand for point-of-care diagnostics and affordable therapeutics. Collaborative partnerships between multinational corporations and regional biotech firms are emerging to establish production facilities and co-development centers, ensuring streamlined market entry and scale-up potential.

Profiling Leading Aptamer Innovators and Strategic Players Driving Competitive Differentiation through Specialized Platforms Collaborations and Technological Investments

Leading innovators in the aptamer sector have differentiated through the synergy of proprietary technologies and strategic alliances. Several specialist providers have built extensive intellectual property portfolios around high-throughput selection platforms and chemical modification techniques, enabling them to offer custom binding solutions for complex targets. Collaborative partnership models with pharmaceutical companies have facilitated co-development of aptamer-drug conjugates and diagnostic assays, accelerating time to market.

Investment in vertically integrated capabilities-spanning automated synthesis, rigorous quality control, and scalable production-has positioned these organizations to meet growing demand while maintaining stringent reproducibility standards. Meanwhile, cross-industry collaborations are increasingly common, with technology providers aligning with contract research organizations and academic centers to broaden application portfolios. By fostering open innovation networks and leveraging combined expertise, these key players are shaping the competitive dynamics of the aptamer market.

Outlining Strategic Recommendations for Industry Leaders to Capitalize on Aptamer Market Evolutions Enhance Competitive Positioning and Foster Collaborative Ecosystems

Industry leaders should prioritize diversification of aptamer selection platforms to mitigate the risks associated with single-technology dependency. By integrating complementary methodologies, organizations can tailor discovery workflows to diverse target classes and accelerate candidate identification. Simultaneously, establishing robust supply chain alliances with multiple regional suppliers will enhance resilience against tariff fluctuations and logistical disruptions.

Forging cross-sector partnerships with diagnostic manufacturers, pharmaceutical developers, and environmental testing laboratories will expand market reach and facilitate co-development of integrated solutions. Engaging early with regulatory authorities to define clear validation paths for aptamer-based products will streamline approval processes and reduce time to commercialization. In parallel, investing in automation and digital analytics-particularly machine learning algorithms for sequence optimization-will drive efficiency gains and elevate candidate quality.

Finally, companies should explore modular platform architectures that support flexible deployment across laboratory and field settings, ensuring that aptamer applications can adapt to emerging needs in point-of-care diagnostics, personalized therapeutics, and real-time environmental monitoring.

Detailing Rigorous Research Methodology Employed to Analyze Aptamer Market Trends Validate Data Sources and Ensure Analytical Transparency and Credibility

The research methodology underpinning this analysis combined a rigorous blend of primary and secondary approaches to ensure comprehensive coverage and analytical integrity. Initial secondary research involved extensive review of scientific literature, patent databases, regulatory guidelines, and white papers to map historical trends and emerging technologies in the aptamer domain. Proprietary databases were consulted to capture validated information on selection platforms, modification chemistries, and application deployments.

Primary research consisted of in-depth interviews with key stakeholders, including academic researchers, technical experts, procurement managers, and C-level executives across biotechnology and pharmaceutical organizations. These qualitative insights were supplemented with detailed case studies of successful product launches, collaborative research initiatives, and supply chain adaptations. Quantitative validation employed triangulation methods to cross-verify data points and identify consensus perspectives.

Throughout the process, data accuracy was reinforced through iterative consultations and peer reviews, ensuring that conclusions reflect both current industry realities and forward-looking projections. This systematic approach provides the transparency and credibility required to support strategic decision making in the rapidly evolving aptamer market.

Summarizing Strategic Insights into the Future Trajectory of Aptamer Technologies Reinforcing the Imperative for Precision Medical and Safety Solutions

The evolution of aptamer technologies is reshaping the landscape of molecular recognition, positioning these versatile agents as cornerstones of next-generation diagnostics, therapeutics, and safety solutions. Technological innovations in selection methodologies and chemical modifications are driving enhanced performance, while adaptive supply chain strategies are mitigating external pressures such as tariff shifts. Segmentation insights highlight the importance of targeted approaches across type, technology, and application dimensions, and regional analysis underscores varied growth trajectories in the Americas, EMEA, and Asia-Pacific.

Key players have distinguished themselves through strategic collaborations, IP development, and platform investments, setting the stage for intensified competition and accelerated commercialization. To navigate this dynamic environment, industry participants must pursue diversified technology portfolios, engage proactively with regulatory bodies, and foster cross-sector partnerships that leverage complementary expertise.

By aligning research priorities with market needs and deploying data-driven procurement and development frameworks, organizations can unlock the full potential of aptamers. This strategic alignment will be vital for driving innovation, achieving operational resilience, and securing leadership positions as the field continues to mature.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aptamers Market, by Type

  • 8.1. Nucleic Acid Aptamers
    • 8.1.1. DNA Aptamers
    • 8.1.2. RNA Aptamers
  • 8.2. Peptide Aptamers

9. Aptamers Market, by Technology

  • 9.1. Non-SELEX-Based Technologies
  • 9.2. SELEX Technology
    • 9.2.1. Capillary Electrophoresis (CE)-SELEX
    • 9.2.2. Capture-SELEX
    • 9.2.3. Cell-SELEX
    • 9.2.4. Graphene Oxide (GO)-SELEX
    • 9.2.5. Microfluidic SELEX
    • 9.2.6. Standard SELEX

10. Aptamers Market, by Application

  • 10.1. Clinical Diagnostics
    • 10.1.1. Cardiovascular & Metabolic Disease Diagnostics
    • 10.1.2. Genetic & Rare Disease Screening
    • 10.1.3. Infectious Disease Diagnostics
    • 10.1.4. Neurological Disorder Diagnostics
    • 10.1.5. Oncology Diagnostics
  • 10.2. Food & Environmental Safety
    • 10.2.1. Agricultural Testing
    • 10.2.2. Environmental Monitoring
    • 10.2.3. Food Safety Testing
  • 10.3. Therapeutics & Drug Development
    • 10.3.1. Cardiovascular Diseases
    • 10.3.2. Infectious Diseases
    • 10.3.3. Neurological Disorders
    • 10.3.4. Oncology
    • 10.3.5. Rare & Genetic Disorders

11. Aptamers Market, by End-User

  • 11.1. Academic & Research Institutions
  • 11.2. Hospital & Clinics
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Aptamers Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Aptamers Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Aptamers Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Aptamers Market

16. China Aptamers Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2024
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2024
  • 17.3. Product Portfolio Analysis, 2024
  • 17.4. Benchmarking Analysis, 2024
  • 17.5. 2bind GmbH
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Aptadel Therapeutics SL
  • 17.8. Aptagen, LLC
  • 17.9. AptaMatrix, Inc.
  • 17.10. Aptamer Group PLC
  • 17.11. AptaTargets SL
  • 17.12. AptusBiotech
  • 17.13. Astellas Pharma Inc.
  • 17.14. Base Pair Biotechnologies, Inc.
  • 17.15. Basking Biosciences
  • 17.16. Bio-Techne Corporation
  • 17.17. Biogenes Technologies Sdn. Bhd.
  • 17.18. Biotage
  • 17.19. Cage Bio, Inc.
  • 17.20. Creative Biogene
  • 17.21. Creative Biolabs
  • 17.22. Drive Therapeutics, LLC
  • 17.23. F. Hoffmann-La Roche AG
  • 17.24. Kaneka Eurogentec S.A.
  • 17.25. NEC Corporation
  • 17.26. NeoVentures Biotechnology Inc.
  • 17.27. NOVAPTECH, S.A.S.
  • 17.28. Profacgen
  • 17.29. SomaLogic, Inc.
  • 17.30. TAGCyx Biotechnologies, Inc.
  • 17.31. Veraptus
  • 17.32. Vivonics Inc.
  • 17.33. Zentek Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 2. GLOBAL APTAMERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL APTAMERS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL APTAMERS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL APTAMERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL APTAMERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL APTAMERS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL APTAMERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL APTAMERS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL APTAMERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 11. UNITED STATES APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 12. CHINA APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)

LIST OF TABLES

  • TABLE 1. GLOBAL APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 2. GLOBAL APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 3. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL APTAMERS MARKET SIZE, BY DNA APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL APTAMERS MARKET SIZE, BY DNA APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL APTAMERS MARKET SIZE, BY DNA APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL APTAMERS MARKET SIZE, BY RNA APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL APTAMERS MARKET SIZE, BY RNA APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL APTAMERS MARKET SIZE, BY RNA APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL APTAMERS MARKET SIZE, BY PEPTIDE APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL APTAMERS MARKET SIZE, BY PEPTIDE APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL APTAMERS MARKET SIZE, BY PEPTIDE APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL APTAMERS MARKET SIZE, BY NON-SELEX-BASED TECHNOLOGIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL APTAMERS MARKET SIZE, BY NON-SELEX-BASED TECHNOLOGIES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL APTAMERS MARKET SIZE, BY NON-SELEX-BASED TECHNOLOGIES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL APTAMERS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS (CE)-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL APTAMERS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS (CE)-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL APTAMERS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS (CE)-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL APTAMERS MARKET SIZE, BY CAPTURE-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL APTAMERS MARKET SIZE, BY CAPTURE-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL APTAMERS MARKET SIZE, BY CAPTURE-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL APTAMERS MARKET SIZE, BY CELL-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL APTAMERS MARKET SIZE, BY CELL-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL APTAMERS MARKET SIZE, BY CELL-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL APTAMERS MARKET SIZE, BY GRAPHENE OXIDE (GO)-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL APTAMERS MARKET SIZE, BY GRAPHENE OXIDE (GO)-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL APTAMERS MARKET SIZE, BY GRAPHENE OXIDE (GO)-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL APTAMERS MARKET SIZE, BY MICROFLUIDIC SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL APTAMERS MARKET SIZE, BY MICROFLUIDIC SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL APTAMERS MARKET SIZE, BY MICROFLUIDIC SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL APTAMERS MARKET SIZE, BY STANDARD SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL APTAMERS MARKET SIZE, BY STANDARD SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL APTAMERS MARKET SIZE, BY STANDARD SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 44. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 46. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 47. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 48. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASE DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 49. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 50. GLOBAL APTAMERS MARKET SIZE, BY GENETIC & RARE DISEASE SCREENING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 51. GLOBAL APTAMERS MARKET SIZE, BY GENETIC & RARE DISEASE SCREENING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 52. GLOBAL APTAMERS MARKET SIZE, BY GENETIC & RARE DISEASE SCREENING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 53. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 54. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 55. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 56. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDER DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 57. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDER DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 58. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDER DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 59. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 60. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 61. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 62. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 63. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 64. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 65. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 66. GLOBAL APTAMERS MARKET SIZE, BY AGRICULTURAL TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 67. GLOBAL APTAMERS MARKET SIZE, BY AGRICULTURAL TESTING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 68. GLOBAL APTAMERS MARKET SIZE, BY AGRICULTURAL TESTING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 69. GLOBAL APTAMERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 70. GLOBAL APTAMERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 71. GLOBAL APTAMERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 72. GLOBAL APTAMERS MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 73. GLOBAL APTAMERS MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 74. GLOBAL APTAMERS MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 75. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 76. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 77. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 78. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 79. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 80. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 81. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 82. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 83. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 84. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 85. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 86. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 87. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 88. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 89. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 90. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 91. GLOBAL APTAMERS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 92. GLOBAL APTAMERS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 93. GLOBAL APTAMERS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 94. GLOBAL APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 95. GLOBAL APTAMERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 96. GLOBAL APTAMERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 97. GLOBAL APTAMERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 98. GLOBAL APTAMERS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 99. GLOBAL APTAMERS MARKET SIZE, BY HOSPITAL & CLINICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 100. GLOBAL APTAMERS MARKET SIZE, BY HOSPITAL & CLINICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 101. GLOBAL APTAMERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 102. GLOBAL APTAMERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 103. GLOBAL APTAMERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 104. GLOBAL APTAMERS MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 105. AMERICAS APTAMERS MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
  • TABLE 106. AMERICAS APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 107. AMERICAS APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 108. AMERICAS APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 109. AMERICAS APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 110. AMERICAS APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 111. AMERICAS APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 112. AMERICAS APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 113. AMERICAS APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 114. AMERICAS APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 115. NORTH AMERICA APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 116. NORTH AMERICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 117. NORTH AMERICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 118. NORTH AMERICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 119. NORTH AMERICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 120. NORTH AMERICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 121. NORTH AMERICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 122. NORTH AMERICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 123. NORTH AMERICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 124. NORTH AMERICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 125. LATIN AMERICA APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 126. LATIN AMERICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 127. LATIN AMERICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 128. LATIN AMERICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 129. LATIN AMERICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 130. LATIN AMERICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 131. LATIN AMERICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 132. LATIN AMERICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 133. LATIN AMERICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 134. LATIN AMERICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 145. EUROPE APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 146. EUROPE APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 147. EUROPE APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 148. EUROPE APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 149. EUROPE APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 150. EUROPE APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 151. EUROPE APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 152. EUROPE APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 153. EUROPE APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 154. EUROPE APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 155. MIDDLE EAST APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 156. MIDDLE EAST APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 157. MIDDLE EAST APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 158. MIDDLE EAST APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 159. MIDDLE EAST APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 160. MIDDLE EAST APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 161. MIDDLE EAST APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 162. MIDDLE EAST APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 163. MIDDLE EAST APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 164. MIDDLE EAST APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 165. AFRICA APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 166. AFRICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 167. AFRICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 168. AFRICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 169. AFRICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 170. AFRICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 171. AFRICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 172. AFRICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 173. AFRICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 174. AFRICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 175. ASIA-PACIFIC APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 176. ASIA-PACIFIC APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 177. ASIA-PACIFIC APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 178. ASIA-PACIFIC APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 179. ASIA-PACIFIC APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 180. ASIA-PACIFIC APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 181. ASIA-PACIFIC APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 182. ASIA-PACIFIC APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 183. ASIA-PACIFIC APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 184. ASIA-PACIFIC APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 185. GLOBAL APTAMERS MARKET SIZE, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 186. ASEAN APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 187. ASEAN APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 188. ASEAN APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 189. ASEAN APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 190. ASEAN APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 191. ASEAN APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 192. ASEAN APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 193. ASEAN APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 194. ASEAN APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 195. ASEAN APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 196. GCC APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 197. GCC APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 198. GCC APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 199. GCC APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 200. GCC APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 201. GCC APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 202. GCC APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 203. GCC APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 204. GCC APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 205. GCC APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 206. EUROPEAN UNION APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 207. EUROPEAN UNION APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 208. EUROPEAN UNION APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 209. EUROPEAN UNION APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 210. EUROPEAN UNION APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 211. EUROPEAN UNION APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 212. EUROPEAN UNION APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 213. EUROPEAN UNION APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 214. EUROPEAN UNION APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 215. EUROPEAN UNION APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 216. BRICS APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 217. BRICS APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 218. BRICS APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 219. BRICS APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 220. BRICS APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 221. BRICS APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 222. BRICS APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 223. BRICS APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 224. BRICS APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 225. BRICS APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 226. G7 APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 227. G7 APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 228. G7 APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 229. G7 APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 230. G7 APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 231. G7 APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 232. G7 APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 233. G7 APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 234. G7 APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 235. G7 APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 236. NATO APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 237. NATO APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 238. NATO APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 239. NATO APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 240. NATO APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 241. NATO APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 242. NATO APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 243. NATO APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 244. NATO APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 245. NATO APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 246. GLOBAL APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 247. UNITED STATES APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 248. UNITED STATES APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 249. UNITED STATES APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 250. UNITED STATES APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 251. UNITED STATES APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 252. UNITED STATES APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 253. UNITED STATES APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 254. UNITED STATES APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 255. UNITED STATES APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 256. UNITED STATES APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 257. CHINA APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 258. CHINA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 259. CHINA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 260. CHINA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 261. CHINA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 262. CHINA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 263. CHINA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 264. CHINA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 265. CHINA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 266. CHINA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)